Table 3.
Characteristic | Likelihood of taking treatment with 1:100 | Likelihood of taking treatment with 1:10,000 | Likelihood of taking treatment with 1:100,000 |
---|---|---|---|
Male vs. female | 0.30 (−0.08, 0.68) | 0.58 (0.08, 1.07)* | 0.60 (0.08, 1.12)* |
Age | 0.01 (−0.01, 0.02) | 0.01 (−0.01, 0.03) | −0.001 (−0.02, 0.02) |
White race vs. other | 0.01 (−0.69, 0.71) | −0.21 (−1.12, 0.71) | −0.14 (−1.12, 0.83) |
Marital status | −0.20 (−0.55, 0.15) | −0.63 (−1.08, −0.18)a | −0.33 (−0.81, 0.15) |
Number of children | −0.02 (−0.16, 0.12) | −0.13 (−0.31, 0.06) | 0.02 (−0.18, 0.21) |
EDSS | 0.02 (−0.05, 0.09) | 0.06 (−0.04, 0.16) | 0.05 (−0.06, 0.16) |
Disease duration | −0.001 (−0.02, 0.02) | −0.001 (−0.02, 0.02) | −0.01 (−0.03, 0.01) |
Disease course (progressive vs. relapsing) | 0.18 (−0.22, 0.58) | 0.40 (−0.12, 0.92) | 0.34 (−0.21, 0.89) |
Relapse rate in previous year | −0.19 (−0.62, 0.25) | 0 (−0.58, 0.58) | 0.23 (−0.39, 0.84) |
Current treatment | |||
Untreated | Reference | Reference | Reference |
IFN | −0.21 (−0.81, 0.39) | −0.18 (−0.95, 0.59) | −0.39 (−1.20, 0.43) |
GA | −0.13 (−0.64, 0.39) | −0.01 (−0.68, 0.66) | −0.36 (−1.06, 0.35) |
NTZ | −0.34 (−0.97, 0.30) | 0.76 (−0.03, 1.55) | 0.74 (−0.04, 1.53) |
FTY | 0.09 (−0.48, 0.67) | 0.50 (−0.27, 1.28) | 0.48 (−0.30, 1.27) |
BG-12 | 0.13 (−0.36, 0.63) | 0.19 (−0.46, 0.84) | 0.45 (−0.22, 1.12) |
TFL | 0.14 (−0.80, 1.08) | 0.93 (−0.29, 2.14) | 0.74 (−0.54, 2.02) |
Other | 0.02 (−0.71, 0.75) | 0.43 (−0.52, 1.37) | 0.56 (−0.43, 1.56) |
Values reported are the estimated linear regression coefficient and associated 95% confidence interval from a model with the characteristic as the predictor and likelihood of taking the treatment as the outcome. These values represent the change in the mean of the outcome for a one unit increase in the predictor. Participants with missing data on a specific covariate were not included in the analysis of that covariate (race: 8; marital status: 7; number of children: 16; EDSS: 24).
Association between predictor and covariate had a p value of less than 0.05.
EDSS: Expanded Disability Status Scale; IFN: interferon; GA: glatiramer acetate; NTZ: natalizumab; FTY: fingolimod; BG-12: dimethyl fumarate; TFL: Teriflunomide.